Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis
Shunji Suzuki, Makoto Suzuki, Norio Hanafusa, Ken Tsuchiya, Kosaku Nitta
Abstract
INTRODUCTION: chondrogenic transition of vascular cells leading to calcification that is unrelated to bone metabolism. This study investigated the long-term effects of denosumab, an osteoprotegerin mimic peptide, on AoAC. METHODS: This study examined 58 patients with an 8 year vintage of dialysis at 1 center for observational study during 2009 to 2020. Denosumab was administered to 28 patients every 6 months. Blood chemical data were used. AoAC proportions were measured using a simple but computed tomography-equivalent computer-based chest X-ray analysis (calcified pieces of areas around the aorta). RESULTS: < 0.01) in the denosumab group. Denosumab effects on decalcification were not observed 12 months after initiation. CONCLUSION: We conclude that long-term use of denosumab is effective to reverse or treat AoAC in patients undergoing hemodialysis.